GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Concord Biotech Ltd

Concord Biotech Ltd Q2 FY27 Consolidated Net Profit at Rs. 6,957.20 lakhs

RESULTS ▲ Positive Development LOW RISK
📅 Filed on BSE: 28 Oct 2026, 02:58 PM IST  ·  BSE ID: aa738c83-ccc3-43f0-afe5-a89eebdb7d7c
View Original BSE Filing (PDF)
💡
In Simple Terms
Concord Biotech announced its financial results for July-September 2026, showing its income and profits for the quarter.
🤖 AI Summary
  • Concord Biotech's Q2 FY27 consolidated total income from operations was Rs. 30,907.02 lakhs.
  • Consolidated Net Profit after Tax for Q2 FY27 stood at Rs. 6,957.20 lakhs.
  • Half year ended September 30, 2026, consolidated total income was Rs. 56,655.92 lakhs.
  • Consolidated Net Profit after Tax for H1 FY27 reached Rs. 12,726.87 lakhs.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Consolidated Total Income from Operations Q2 FY27
30,907.02 lakhs
25.10%
Consolidated Net Profit (Loss) for the period after tax Q2 FY27
6,957.20 lakhs
10.32%
Consolidated Total Income from Operations H1 FY27
56,655.92 lakhs
25.60%
Consolidated Net Profit (Loss) for the period after tax H1 FY27
12,726.87 lakhs
18.73%
Consolidated Earnings Per Share (Basic) Q2 FY27
6.71
10.05%
🏢 How This Affects the Company
💰
Financial Impact
The company's consolidated net profit after tax for Q2 FY27 was Rs. 6,957.20 lakhs. For the half year, consolidated net profit after tax was Rs. 12,726.87 lakhs.
👥 What This Means For Shareholders
✅
Action Required
No specific action is required from shareholders based on this financial results filing.
👤
Who Is Affected
Shareholders are affected by the company's financial performance, which shows a consolidated net profit after tax of Rs. 6,957.20 lakhs for Q2 FY27.
🔍
Management Signal
The financial results indicate management's focus on operational growth and profitability for the reported periods.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Q3 FY27 financial results — review consolidated total income trend.
Investor presentation for Q3 FY27 — assess management's outlook.
Any further board meeting outcomes regarding capital allocation.
LOW RISK The filing reports routine quarterly financial results with growth in key metrics.
💡 Investor Takeaway
Concord Biotech reported Q2 FY27 consolidated total income from operations of Rs. 30,907.02 lakhs, a 25.10% increase from Q2 FY26. Consolidated Net Profit after Tax for Q2 FY27 stood at Rs. 6,957.20 lakhs, up 10.32% from Q2 FY26.
⚖️ Strengths & Concerns

✅ Positives

  • Q2 FY27 consolidated total income from operations increased to Rs. 30,907.02 lakhs from Rs. 24,705.75 lakhs in Q2 FY26.
  • Consolidated Net Profit after Tax for Q2 FY27 rose to Rs. 6,957.20 lakhs from Rs. 6,306.28 lakhs in Q2 FY26.
📅 Company Track Record
Concord Biotech was recently listed, with its IPO in August 2023. Past filings indicate Q1 FY27 consolidated revenue rose 26% to Rs. 257.5 Crs and PAT up 31%. Q2 FY27 consolidated revenue rose 25.1% to Rs. 309.1 Crs and PAT increased 10.3%.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Concord Biotech's consolidated net profit in Q2 FY27?
Concord Biotech reported a consolidated Net Profit after Tax of Rs. 6,957.20 lakhs for the second quarter ended September 30, 2026.
What was the total income from operations for Concord Biotech in Q2 FY27?
The consolidated total income from operations for Concord Biotech in Q2 FY27 was Rs. 30,907.02 lakhs.
How did Concord Biotech's half-year consolidated net profit compare to the prior year?
For the half year ended September 30, 2026, consolidated Net Profit after Tax was Rs. 12,726.87 lakhs, compared to Rs. 10,720.07 lakhs for the half year ended September 30, 2025, marking an 18.73% increase.
What was Concord Biotech's basic Earnings Per Share (EPS) in Q2 FY27?
Concord Biotech's consolidated basic Earnings Per Share was Rs. 6.71 for Q2 FY27, compared to Rs. 6.10 in Q2 FY26.

Questions based on this BSE filing only. For information purposes.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.